DR-18 for Leukemia
Trial Summary
The trial protocol does not specify if you need to stop your current medications. However, you cannot have had cellular immunotherapy or new targeted therapy in the 4 weeks before enrolling. It's best to discuss your current medications with the trial team.
The available research does not provide specific data on DR-18 for Leukemia. However, studies on a similar treatment, interleukin-2 (IL-2), show that it can lead to complete remission in some patients with acute myeloid leukemia (AML) who have a low level of disease. For example, one study found that 8 out of 14 patients achieved complete remission, with some maintaining remission for over 30 months. This suggests that IL-2 can be effective in certain cases, but the research also highlights significant side effects and limited success in more advanced cases. Therefore, while IL-2 shows some promise, further research is needed to determine the effectiveness of DR-18 specifically.
12345The available research does not directly provide safety data for DR-18 or Decoy-resistant interleukin-18 in leukemia. However, a phase 1 study of recombinant human IL-18 (rhIL-18) demonstrated immunomodulatory and clinical activity, which may be relevant since DR-18 is a form of IL-18. No specific safety data for DR-18 in leukemia is mentioned in the provided studies.
36789Eligibility Criteria
This trial is for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or persisted after a stem cell transplant. Participants must have had the transplant as their prior treatment.Inclusion Criteria
Exclusion Criteria